Vancouver-based psychedelic drugs company Clearmind Medicine announced its plans to raise USD 7.5 million via an underwritten public offering consisting of 1.2 million common shares priced at USD 6.50 per share. The company has offered a 45-day option to purchase an additional 15% (173,077) of common shares to Aegis Capital Corp which is also acting as the sole book-running manager for the offering.
Furthermore, the company will also offer Aegis up to 57,692 warrants, with each warrant equivalent to one common share upon payment of USD 8.125 per share.
Clearmind, which was listed on the Canadian Securities, has now been uplisted to the Nasdaq Capital Market with effect November 15, 2022, under the symbol “CMND”.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.